{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "73edf999",
   "metadata": {},
   "source": [
    "### Search and make a summary of 10 articles about sepsis diagnosis\n",
    "7 articles are about all possible markers and 3 about gene expression level\n",
    "\n",
    "#### 11.Biomarkers of Sepsis\n",
    "journal Critical Care Medicine\n",
    "\n",
    "\n",
    "Pro-Inflammatory Cytokines and Chemokines\n",
    "\n",
    "**Tumor Necrosis Factor (TNF)\n",
    "Interleukin-1 beta (IL-1β)\n",
    "Interleukin-6 (IL-6)\n",
    "Interleukin-8 (IL-8)\n",
    "Monocyte Chemoattractant Protein-1 (MCP-1)**\n",
    "\n",
    "\n",
    "Anti-Inflammatory Cytokines\n",
    "\n",
    "**Interleukin-10 (IL-10)\n",
    "Gene: IL10\n",
    "Transforming Growth Factor-beta (TGF-β)\n",
    "Gene: TGFB1**\n",
    "\n",
    "Acute Phase Proteins\n",
    "\n",
    "**C-Reactive Protein (CRP)\n",
    "Gene: CRP\n",
    "Procalcitonin (PCT)\n",
    "Gene: CALCA\n",
    "Pentraxin 3 (PTX3)\n",
    "Gene: PTX3**\n",
    "\n",
    "Neutrophil and Monocyte Activation Markers\n",
    "\n",
    "**CD64 (Fcγ Receptor I)\n",
    "Gene: FCGR1A\n",
    "Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1)\n",
    "Gene: TREM1\n",
    "CD11b (Integrin alpha M)\n",
    "Gene: ITGAM**\n",
    "\n",
    "Endothelial and Coagulation Markers\n",
    "\n",
    "**D-dimer\n",
    "Marker for fibrinolysis; no single gene association.\n",
    "Thrombomodulin (TM)\n",
    "Gene: THBD**\n",
    "\n",
    "Damage-Associated Molecular Patterns (DAMPs)\n",
    "\n",
    "**High Mobility Group Box 1 (HMGB1)\n",
    "Gene: HMGB1\n",
    "S100 Proteins (e.g., Calgranulins)\n",
    "Genes: S100A8, S100A9**\n",
    "\n",
    "Other Biomarkers\n",
    "\n",
    "**Heparin-Binding Protein (HBP, Azurocidin)\n",
    "Gene: AZU1\n",
    "Receptor for Advanced Glycation End-products (RAGE)\n",
    "Gene: AGER\n",
    "Lipopolysaccharide-Binding Protein (LBP)\n",
    "Gene: LBP\n",
    "Soluble CD14 (sCD14)\n",
    "Gene: CD14**\n",
    "\n",
    "Markers of Immune Suppression\n",
    "\n",
    "**HLA-DR (Human Leukocyte Antigen - DR)\n",
    "Gene: HLA-DRA\n",
    "Programmed Death-1 (PD-1)\n",
    "Gene: PDCD1\n",
    "Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4)\n",
    "Gene: CTLA4**\n",
    "\n",
    "Genes Related to Metabolic Dysregulation\n",
    "\n",
    "**Lactate (Indicator of tissue hypoxia, not directly gene-related)**.\n",
    "\n",
    "\n",
    "#### 12.Bench-to-bedside review: Future novel diagnostics for sepsis – a systems biology approach\n",
    "published in Critical Care\n",
    "\n",
    "1. Genomics\n",
    "\n",
    "Genomics involves studying genetic predisposition to sepsis using techniques like SNP analysis and GWAS.\n",
    "Biomarkers and Genes:\n",
    "SNPs (Single Nucleotide Polymorphisms):\n",
    "**SNPs in IL-2 (Interleukin-2) gene**: Associated with increased susceptibility to bacteremia, malaria, and tuberculosis.\n",
    "**TNF (Tumor Necrosis Factor) gene**:SNP at position -308 in the promoter region associated with higher TNFα expression, leading to increased mortality in septic shock.\n",
    "**TLR4 (Toll-Like Receptor 4)**:SNPs linked to impaired immune response and gram-negative septic shock susceptibility.\n",
    "**CD14**: SNPs in the CD14 locus are associated with susceptibility to septic shock and higher mortality.\n",
    "Protein C Gene (-1641 AA Polymorphism): Linked to decreased survival, increased organ dysfunction, and systemic inflammation in severe sepsis.\n",
    "Diagnostic Value:\n",
    "SNPs offer insights into genetic predisposition but have limited diagnostic utility without further validation.\n",
    "Useful for risk stratification and designing personalized therapeutic approaches.\n",
    "\n",
    "2. Epigenomics\n",
    "\n",
    "Epigenomics studies reversible DNA modifications (e.g., methylation and histone modifications) that influence gene activity.\n",
    "Biomarkers and Genes:\n",
    "**NF-κB (Nuclear Factor Kappa B)**:Epigenetically regulated through histone phosphorylation and acetylation.\n",
    "Central to cytokine production in sepsis, including IL-6.\n",
    "\n",
    "DNA Methylation in CpG Islands:Promoters of cytokine-related genes show altered methylation patterns affecting transcription.\n",
    "Diagnostic Value:\n",
    "Epigenetic markers are promising but require tissue-specific studies and tools for clinical application.\n",
    "\n",
    "3. Transcriptomics\n",
    "\n",
    "Transcriptomics quantifies gene expression levels through mRNA and miRNA profiling.\n",
    "Biomarkers and Genes:\n",
    "\n",
    "mRNA Expression:\n",
    "28-gene signature: Identified as upregulated in survivors versus non-survivors of septic shock.\n",
    "Altered expression in over 500 genes in septic patients, including cytokine and signal transduction genes.\n",
    "\n",
    "miRNA Expression:\n",
    "**miR-150**: Significantly downregulated in sepsis and correlates with organ failure scores.\n",
    "**miR-146b**: Downregulated during endotoxemia.\n",
    "**miR-143**: Upregulated in response to endotoxin.\n",
    "**miR-342**: Downregulated in immune cells during sepsis.\n",
    "**let-7g**: Downregulated in sepsis patients.\n",
    "Diagnostic Value:\n",
    "miR-150 is a strong prognostic marker for disease severity.\n",
    "mRNA signatures are useful for early diagnosis but lack consistency across studies.\n",
    "\n",
    "4. Proteomics\n",
    "\n",
    "Proteomics focuses on protein profiling and discovery.\n",
    "Biomarkers and Genes:\n",
    "Known Biomarkers:\n",
    "\n",
    "**Procalcitonin (PCT)**: An established marker for bacterial infections.\n",
    "**C-Reactive Protein (CRP)**: A general marker of inflammation.\n",
    "Novel Proteins Identified:\n",
    "Plasma proteins with differential expression between survivors and non-survivors.\n",
    "Cytokines and other uncharacterized proteins.\n",
    "Diagnostic Value:\n",
    "PCT and CRP are routinely used but lack specificity for sepsis.\n",
    "Emerging proteins show promise for stratifying patients but require further study.\n",
    "\n",
    "5. Metabolomics\n",
    "\n",
    "Metabolomics studies small molecules (metabolites) involved in cellular processes.\n",
    "Biomarkers:\n",
    "**Glutathione**: Identified in sepsis-induced acute lung injury.\n",
    "**Adenosine**: Altered levels in sepsis.\n",
    "**Phosphatidylserine**: Changes associated with inflammatory states.\n",
    "**Sphingomyelin**: Distinct levels observed in sepsis patients versus healthy controls.\n",
    "Diagnostic Value:\n",
    "Metabolomics biomarkers reflect downstream metabolic changes in sepsis.\n",
    "Promising for disease progression monitoring and therapeutic response prediction.\n",
    "\n",
    "Conclusion\n",
    "The article identifies numerous biomarkers across genomics, epigenomics, transcriptomics, proteomics, and metabolomics. While many biomarkers show potential for diagnosis and prognosis, their clinical application remains limited without large-scale validation studies. Combining these markers into multi-omics panels offers the greatest promise for improving sepsis diagnosis, risk stratification, and personalized treatment.\n",
    "\n",
    "#### 13.Enhancing Sepsis Biomarker Development: Key Considerations from Public and Private Perspectives\n",
    "published in Critical Care (2024)\n",
    "\n",
    "Biomarkers Discussed\n",
    "1. Established Biomarkers\n",
    "\n",
    "**Procalcitonin (PCT)**:Diagnostic for bacterial sepsis.\n",
    "Limited standalone utility but useful when combined with clinical scores.\n",
    "Plays a role in guiding antimicrobial stewardship.\n",
    "\n",
    "**C-Reactive Protein (CRP)**:\n",
    "Non-specific inflammation marker.\n",
    "Used in neonatal and adult sepsis diagnosis.\n",
    "\n",
    "**Presepsin**:\n",
    "Promising for early sepsis diagnosis due to its rapid rise during the host immune response.\n",
    "\n",
    "2. Emerging and Experimental Biomarkers\n",
    "\n",
    "**sTREM-1** (Soluble Triggering Receptor Expressed on Myeloid Cells-1):Elevated in septic shock and used to guide therapies like Nangibotide.\n",
    "\n",
    "**Adrenomedullin (ADM)**:High levels associated with increased mortality.\n",
    "Used in trials to guide treatment with Enibarcimab.\n",
    "\n",
    "**Circulating Nucleosomes**:Associated with sepsis-associated organ dysfunction.\n",
    "\n",
    "**HLA-DR Expression**:Reflects immune suppression in sepsis.\n",
    "Potential for predicting response to immunomodulatory treatments.\n",
    "\n",
    "gene Biomarkers in Sepsis\n",
    "The article highlights the growing importance of gene biomarkers in understanding sepsis pathophysiology, particularly through genomics and transcriptomics approaches. These biomarkers have diagnostic and prognostic potential, reflecting the host immune response and infection-specific dynamics.\n",
    "\n",
    "1. Genes Mentioned in Transcriptomics Studies\n",
    "Genes Identified as Biomarkers:\n",
    "\n",
    "**S100A8**:Encodes a calgranulin protein involved in neutrophil activation and inflammatory responses.\n",
    "Overexpressed during septic shock, reflecting immune activation.\n",
    "\n",
    "**S100A12**:Encodes another calgranulin protein linked to neutrophil-mediated inflammation.\n",
    "Elevated levels correlate with severe immune responses in septic patients.\n",
    "\n",
    "**CD74**:Encodes the invariant chain of MHC class II molecules.\n",
    "Downregulation during sepsis is associated with immune suppression and recovery trajectories.\n",
    "\n",
    "**HLA-DR**:Encodes a major histocompatibility complex (MHC) class II protein essential for antigen presentation.\n",
    "Reduced expression correlates with sepsis-induced immune suppression and worse outcomes.\n",
    "\n",
    "**IL6**:Encodes Interleukin-6, a pro-inflammatory cytokine central to immune responses.\n",
    "A long-studied marker for sepsis severity and disease progression.\n",
    "\n",
    "**TNF**:Encodes Tumor Necrosis Factor-alpha, a pro-inflammatory cytokine that contributes to sepsis pathophysiology.\n",
    "Persistently elevated levels are linked to poor outcomes.\n",
    "\n",
    "**miR-150**A microRNA (non-coding RNA) downregulated in sepsis patients.\n",
    "Associated with organ dysfunction and severity of disease.\n",
    "\n",
    "**miR-146a**:\n",
    "A microRNA involved in regulating inflammation.\n",
    "Altered expression levels observed in septic patients.\n",
    "\n",
    "2. Genes Mentioned in Genomic Studies\n",
    "Genetic Variants (SNPs) Associated with Sepsis Susceptibility:\n",
    "\n",
    "**TLR4 (Toll-Like Receptor 4)**:Polymorphisms in this gene affect pathogen recognition, particularly in gram-negative sepsis.\n",
    "Associated with immune response dysregulation and increased susceptibility to septic shock.\n",
    "\n",
    "**CD14**:Polymorphisms in this gene are linked to altered immune responses and increased risk of septic shock.\n",
    "\n",
    "**IL6 (Interleukin-6)**:Polymorphisms in the promoter region impact cytokine production and severity of inflammation.\n",
    "\n",
    "**TNF (Tumor Necrosis Factor-alpha)**:Polymorphisms in the promoter region (e.g., -308 position) correlate with higher TNF production and increased septic shock mortality.\n",
    "\n",
    "**Protein C Gene**:Polymorphisms in the promoter region (e.g., -1641 AA) are associated with reduced survival, increased organ dysfunction, and systemic inflammation in severe sepsis.\n",
    "\n",
    "3. Diagnostic Value of Gene Biomarkers\n",
    "Strengths:\n",
    "Gene biomarkers provide dynamic insights into sepsis progression:\n",
    "S100A8 and S100A12: Reflect ongoing inflammation.\n",
    "CD74 and HLA-DR: Indicate immune suppression and recovery potential.\n",
    "miR-150 and miR-146a: Offer non-coding RNA perspectives, useful for predicting severity.\n",
    "Limitations:\n",
    "SNPs in TLR4, CD14, IL6, and TNF are useful for understanding sepsis susceptibility but lack standalone diagnostic reliability.\n",
    "Gene expression changes in septic patients vary across populations and require validation in larger studies.\n",
    "\n",
    "#### 14.Early Diagnosis of Sepsis: Is an Integrated Omics Approach the Way Forward?\n",
    "published in Molecular Diagnosis & Therapy in 2017\n",
    "\n",
    "1. Current Challenges in Sepsis Diagnosis\n",
    "Existing biomarkers like lactate lack specificity.\n",
    "Clinical definitions such as Sepsis-3 criteria are not predictive of patient outcomes.\n",
    "Misdiagnosis can lead to overtreatment with antimicrobials, contributing to antimicrobial resistance.\n",
    "\n",
    "2. Multi-Omics Integration\n",
    "\n",
    "A. Genomics\n",
    "Genomic studies identify single nucleotide polymorphisms (SNPs) that influence sepsis susceptibility and outcomes.\n",
    "Genes Mentioned:\n",
    "\n",
    "**TLR4 (Toll-Like Receptor 4)**: Associated with immune response dysregulation and susceptibility to gram-negative infections.\n",
    "\n",
    "**TLR2 (Toll-Like Receptor 2)**: Similar involvement in pathogen recognition.\n",
    "\n",
    "**CCR5 (C-C Chemokine Receptor Type 5)**: Implicated in immune modulation.\n",
    "\n",
    "**CFP (Complement Factor Properdin)**: Linked to complement activation and infection severity.\n",
    "\n",
    "**SLC11A1 (Solute Carrier Family 11 Member A1)**: Associated with intracellular pathogen resistance.\n",
    "\n",
    "B. Transcriptomics\n",
    "Transcriptomics evaluates changes in gene expression to predict sepsis outcomes and differentiate between bacterial and viral infections.\n",
    "\n",
    "Key Transcriptomic Findings:\n",
    "Host Gene Expression Signatures: Differentiate between sepsis survivors and non-survivors.\n",
    "\n",
    "miRNAs:\n",
    "\n",
    "**miR-223**: Anti-inflammatory; protects against excessive immune activation.\n",
    "**miR-146a**: Regulates inflammatory signaling pathways.\n",
    "\n",
    "C. Proteomics\n",
    "\n",
    "Proteomics identifies proteins that are upregulated or downregulated during sepsis.\n",
    "Proteins Identified:\n",
    "\n",
    "**Cardiolipin**: Mitochondrial membrane component linked to organ dysfunction.\n",
    "\n",
    "**Mitochondrial DNA (mtDNA)**: Released during cell damage; acts as a damage-associated molecular pattern (DAMP).\n",
    "\n",
    "D. Metabolomics\n",
    "\n",
    "Metabolomics evaluates biochemical changes in small molecules.\n",
    "Key Metabolites:\n",
    "\n",
    "**Carnitine Esters**: Indicators of mitochondrial dysfunction.\n",
    "\n",
    "**Bile Acids**: Elevated in non-survivors.\n",
    "\n",
    "**Nicotinamide Adenine Dinucleotide (NAD+)**: Associated with energy metabolism disruptions.\n",
    "\n",
    "**Tricarboxylic Acid (TCA) Cycle Intermediates:** Suggest an energy crisis in non-survivors.\n",
    "\n",
    "3. Diagnostic Value of Biomarkers\n",
    "\n",
    "**Lactate**: Still a widely used marker, but its lack of specificity necessitates complementary biomarkers.\n",
    "Integrated Panels:\n",
    "Combining host gene expression, metabolomic data, and proteomic findings improves diagnostic accuracy.\n",
    "\n",
    "4. Relationship Between Genetic Variations and Outcomes\n",
    "\n",
    "Rare genetic variants, such as loss-of-function mutations, are implicated in sepsis susceptibility.\n",
    "Key Examples:\n",
    "\n",
    "**DDAH2 (Dimethylarginine Dimethylaminohydrolase 2)**: SNP in the promoter region affects nitric oxide metabolism and outcomes.\n",
    "\n",
    "**PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)**: Modulates lipid metabolism and cytokine production, influencing survival.\n",
    "\n",
    "5. Mitochondrial Dysfunction and Muscle Loss\n",
    "\n",
    "Key Points Discussed:\n",
    "Overview:\n",
    "\n",
    "Mitochondria play a critical role in energy metabolism, especially in tissues like muscles.\n",
    "In septic shock survivors, mitochondrial dysfunction is a significant contributor to long-term complications, including muscle loss (myopathy).\n",
    "Mechanisms of Mitochondrial Dysfunction in Sepsis:\n",
    "\n",
    "Reactive Oxygen Species (ROS):Overproduction during sepsis damages mitochondrial DNA (mtDNA), proteins, and lipids, impairing mitochondrial function.\n",
    "\n",
    "Mitochondrial Membrane Potential Collapse:Damage disrupts the electron transport chain, leading to decreased ATP production.\n",
    "\n",
    "Release of mtDNA:Damaged mitochondria release mtDNA into circulation, where it acts as a damage-associated molecular pattern (DAMP), further fueling inflammation.\n",
    "\n",
    "Impact on Muscle:Loss of mitochondrial efficiency leads to impaired energy production in skeletal muscles.\n",
    "Prolonged mitochondrial dysfunction contributes to critical illness myopathy (CIM), characterized by:\n",
    "Loss of muscle mass.\n",
    "Reduced muscle strength.\n",
    "Long-term physical disability in septic shock survivors.\n",
    "\n",
    "Biomarkers of Mitochondrial Dysfunction:\n",
    "\n",
    "**Cardiolipin**: A key mitochondrial membrane lipid, disrupted during sepsis.\n",
    "\n",
    "**Circulating mtDNA**: Indicates mitochondrial injury and systemic inflammation.\n",
    "\n",
    "**Carnitine Esters**: Reflect mitochondrial energy metabolism dysfunction.\n",
    "\n",
    "Therapeutic Considerations:\n",
    "Interventions to restore mitochondrial function, such as antioxidants or metabolic support, could mitigate muscle loss in septic patients.\n",
    "\n",
    "\n",
    "#### 15.The Use of Biomarkers in the Diagnosis and Management of Sepsis\n",
    "International Journal of Biomedical Laboratory Science 2020(not found)\n",
    "\n",
    "1. Inflammatory Biomarkers\n",
    "Biomarkers linked to inflammation, though non-specific for sepsis.\n",
    "\n",
    "**Lactate**\n",
    "Role: A metabolite of glucose elevated in anaerobic metabolism.\n",
    "Clinical Use: Elevated lactate (>4 mmol/L) predicts higher mortality in sepsis and indicates tissue hypoxia.\n",
    "Limitations: Non-specific; must be assessed with clinical context.\n",
    "\n",
    "**C-Reactive Protein (CRP)**\n",
    "Protein Role: Acute-phase protein produced by the liver in response to cytokines like IL-6.\n",
    "Function: Enhances phagocytosis by binding microbial phosphocholine and damaged cells.\n",
    "Clinical Use: Inflammation marker; moderately elevated in chronic conditions and peaks in infections after 12–24 hours.\n",
    "Gene: CRP\n",
    "High-Sensitivity CRP (hsCRP)\n",
    "Similar to CRP but offers more sensitivity for low-grade inflammation.\n",
    "\n",
    "**Procalcitonin (PCT)**\n",
    "Protein Role: Precursor of calcitonin produced in bacterial infections.\n",
    "Function: Differentiates bacterial from non-bacterial infections; rapidly elevated in sepsis.\n",
    "Clinical Use: Guides antibiotic therapy initiation and discontinuation.\n",
    "Gene: CALCA\n",
    "\n",
    "**Heparin-Binding Protein (HBP)**\n",
    "Protein Role: Found in neutrophil granules.\n",
    "Function: Induces vascular leakage and promotes immune cell chemotaxis.\n",
    "Clinical Use: Indicates neutrophil activation; elevated levels correlate with severe infections.\n",
    "\n",
    "2. Immune Response Biomarkers\n",
    "\n",
    "Markers reflecting immune dysregulation during sepsis.\n",
    "\n",
    "**Interleukin-6 (IL-6)**\n",
    "Role: Cytokine produced by macrophages, monocytes, and others during inflammation.\n",
    "Function: Stimulates acute-phase protein production and B-cell differentiation.\n",
    "Clinical Use: Rapidly rises during infection and drops as inflammation resolves.\n",
    "Gene: IL6\n",
    "\n",
    "**Interleukin-8 (IL-8)**\n",
    "Role: Chemokine for neutrophil recruitment to inflammation sites.\n",
    "Function: Enhances phagocytosis and predicts pediatric sepsis outcomes.\n",
    "Clinical Use: Specialized marker; high levels correlate with organ failure risk.\n",
    "Gene: CXCL8\n",
    "\n",
    "**Interleukin-10 (IL-10)**\n",
    "Role: Anti-inflammatory cytokine.\n",
    "Function: Regulates T-cell cytokine production and promotes B-cell survival.\n",
    "Clinical Use: Differentiates SIRS from sepsis.\n",
    "Gene: IL10\n",
    "\n",
    "**Presepsin (sCD14)**\n",
    "Role: Soluble form of CD14 protein on macrophages.\n",
    "Function: Early marker distinguishing bacterial sepsis from SIRS.\n",
    "Clinical Use: Elevated levels predict mortality and bacterial infection severity.\n",
    "Gene: CD14\n",
    "\n",
    "**Monocyte Chemoattractant Protein-1 (MCP-1/CCL2)**\n",
    "Role: Chemokine for recruiting monocytes to infection sites.\n",
    "Function: Linked to inflammation and SOFA scores.\n",
    "Clinical Use: Predicts severity and outcomes in sepsis patients.\n",
    "Gene: CCL2\n",
    "\n",
    "**CD64 (FcγRI)**\n",
    "Role: High-affinity receptor for IgG.\n",
    "Function: Promotes antigen capture and immune cell activation.\n",
    "Clinical Use: Differentiates bacterial infections from other causes.\n",
    "Gene: FCGR1A\n",
    "\n",
    "**Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR/CD87)**\n",
    "Role: Found on immune cells and tumor cells.\n",
    "Function: Elevated in bacterial infections; levels >8 ng/mL predict poor prognosis.\n",
    "Clinical Use: Indicator of mortality risk.\n",
    "Gene: PLAUR\n",
    "\n",
    "**Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1)**\n",
    "Role: Found on neutrophils and monocytes.\n",
    "Function: Upregulated in bacterial infections but not in non-infectious inflammation.\n",
    "Clinical Use: Helps distinguish sepsis from non-infectious SIRS.\n",
    "Gene: TREM1\n",
    "\n",
    "3. Application in Therapy and Prognosis\n",
    "Combination Biomarker Panels\n",
    "Suggested combinations: PCT, presepsin, CD64, suPAR, and sTREM-1.\n",
    "Panels improve diagnostic and prognostic accuracy compared to single markers.\n",
    "Procalcitonin for Antibiotic Guidance\n",
    "Low PCT levels (<0.5 μg/L) indicate no need for antibiotics.\n",
    "High PCT levels (>2 μg/L) necessitate immediate antibiotic initiation.\n",
    "\n",
    "\n",
    "#### 16.Sepsis Biomarkers: An Omics Perspective\n",
    "Frontiers of Medicine (2014)\n",
    "\n",
    "2. Traditional Biomarkers\n",
    "\n",
    "**C-Reactive Protein (CRP)**:Produced in response to IL-6.\n",
    "Indicates infection and inflammation but lacks specificity for sepsis.\n",
    "\n",
    "**Procalcitonin (PCT)**:Elevated in bacterial infections.\n",
    "A useful early marker but not definitive.\n",
    "\n",
    "Cytokines:\n",
    "Includes **TNF-α, IL-1β, IL-6, IL-10, and Osteopontin**.Reflect immune system activity but are non-specific.\n",
    "\n",
    "Chemokines:\n",
    "Macrophage Migration Inhibitory Factor **(MIF)** and High-Mobility Group Box 1 **(HMGB1)** are elevated in sepsis.\n",
    "\n",
    "Soluble Receptors:\n",
    "**sTREM-1 **(soluble Triggering Receptor Expressed on Myeloid cells-1) and **suPAR** (soluble Urokinase-Type Plasminogen Activator Receptor) aid in differentiating sepsis from other conditions.\n",
    "\n",
    "3. Genomics\n",
    "\n",
    "Single Nucleotide Polymorphisms (SNPs):\n",
    "Genetic polymorphisms influence sepsis susceptibility, severity, and outcomes.\n",
    "Key Genes and Variants Identified:\n",
    "\n",
    "**CD14**: Variants associated with susceptibility to sepsis in trauma patients.\n",
    "\n",
    "**TLR4 and TNF-α**: Linked to increased risk of sepsis in burn patients.\n",
    "\n",
    "**TLR1**: SNPs predict higher mortality in gram-positive bacterial sepsis.\n",
    "\n",
    "**VEGF+936CC**: Associated with acute kidney injury in septic patients.\n",
    "\n",
    "IL-6, TLR4, and TNF-α SNPs: Correlated with severity and survival in burn-related sepsis.\n",
    "\n",
    "Epigenetics:\n",
    "DNA Methylation and Histone Modifications regulate immune and inflammatory genes.\n",
    "Epigenetic changes during sepsis contribute to long-term immunosuppression and affect host defenses.\n",
    "\n",
    "4. Transcriptomics\n",
    "Gene Expression Profiles:\n",
    "\n",
    "Analysis of mRNA levels reveals immune system status and disease progression.\n",
    "Key Findings:\n",
    "\n",
    "Upregulated Genes in Sepsis:\n",
    "**IL-1β, IL-6, IL-8, IL-10, TNF-α, FasL, and CCL2**.\n",
    "\n",
    "42-Gene Panel:\n",
    "Differentiates sepsis from inflammation and predicts sepsis before clinical manifestation.\n",
    "\n",
    "MicroRNAs (miRNAs):Post-transcriptional regulators of gene expression.\n",
    "Key miRNAs Identified:\n",
    "**miR-150**: Reduced levels correlate with disease severity.\n",
    "**miR-146a and miR-223**: Reduced in sepsis, potential as early diagnostic markers.\n",
    "**miR-574-5p and miR-297**: Associated with sepsis prognosis.\n",
    "\n",
    "Long Non-Coding RNAs (lncRNAs):\n",
    "Emerging biomarkers; regulate immune responses during infections.\n",
    "\n",
    "5. Proteomics\n",
    "\n",
    "Examines the complete set of proteins expressed in cells and tissues during sepsis.\n",
    "Key Proteins Identified:\n",
    "**YKL-40**: Elevated in septic patients, linked to disease severity.\n",
    "**Cytoskeletal** and **Antioxidant Proteins**: Identified in experimental sepsis models.\n",
    "\n",
    "6. Metabolomics\n",
    "\n",
    "Focuses on metabolites (molecular weight <1000 Da) that reflect biochemical changes during sepsis.\n",
    "Key Metabolites Identified:\n",
    "Energy Metabolites: **Free fatty acids, glucose, and creatine** levels correlate with disease progression.\n",
    "**Polyunsaturated Fatty Acids**: Reflect anti-inflammatory responses.\n",
    "\n",
    "7. Clinical Applications\n",
    "\n",
    "Combining Biomarkers: Using multiple biomarkers (e.g., sTREM-1, suPAR, PCT, and CRP) improves diagnostic sensitivity and specificity.\n",
    "Omics Integration: Combining genomics, transcriptomics, proteomics, and metabolomics offers a holistic understanding of sepsis.\n",
    "\n",
    "8. Challenges and Future Directions\n",
    "Validation Issues:\n",
    "Many biomarkers require clinical validation before routine use.\n",
    "Cost and Accessibility:\n",
    "High costs of multi-omics limit widespread adoption.\n",
    "Heterogeneity:\n",
    "Sepsis varies widely across patients, complicating biomarker generalizability.\n",
    "\n",
    "#### 17. Identification of MicroRNA as Sepsis Biomarker Based on miRNA Regulatory Network Analysis\n",
    " published in BioMed Research International (2014)\n",
    "\n",
    "Materials and Methods\n",
    "\n",
    "Data Collection:\n",
    "miRNA expression profiles from the EBI ArrayExpress database (E-TABM-713), including 8 sepsis patients and 8 healthy controls.\n",
    "\n",
    "Bioinformatics Tools:\n",
    "miRNA-mRNA regulatory data from multiple databases: miRecords, TarBase, miR2Disease, and miRTarBase.\n",
    "Enrichment analyses using DAVID, GeneGo, and PINA (Protein Interaction Network Analysis).\n",
    "\n",
    "4. Results\n",
    "\n",
    "A. Known miRNA Biomarkers in Sepsis\n",
    "The authors identified 10 miRNAs previously validated as sepsis biomarkers:\n",
    "**miR-15a (upregulated in sepsis).\n",
    "miR-16 (upregulated in sepsis).\n",
    "miR-122 (downregulated in sepsis).\n",
    "miR-146a (downregulated in sepsis).\n",
    "miR-223 (downregulated in sepsis).\n",
    "miR-483-5p (downregulated in survivors).\n",
    "miR-499-5p (downregulated in sepsis).\n",
    "miR-574-5p (upregulated in survivors).\n",
    "miR-150 (downregulated in sepsis).\n",
    "*miR-193b (downregulated in survivors).**\n",
    "\n",
    "\n",
    "B. Novel Candidate miRNA Biomarkers for Sepsis\n",
    "The study identified 10 novel candidate miRNAs based on significant differential expression and regulatory network properties:\n",
    "\n",
    "**let-7b\n",
    "miR-15b\n",
    "miR-16\n",
    "miR-145\n",
    "miR-146a\n",
    "miR-210\n",
    "miR-324-3p\n",
    "miR-340\n",
    "miR-484\n",
    "miR-486-5p**\n",
    "\n",
    "Diagnostic Potential:\n",
    "Evaluated using ROC analysis, with area under the curve (AUC) values ranging from 0.81 to 0.97, indicating high diagnostic accuracy.\n",
    "\n",
    "C. Pathway and Disease Ontology Analysis\n",
    "\n",
    "Pathway Analysis:\n",
    "\n",
    "Target genes of candidate miRNAs were enriched in pathways related to:\n",
    "Immune response: TLR signaling, HMGB1 signaling, IL-1 signaling.\n",
    "Apoptosis: Regulation of programmed cell death.\n",
    "Development: Angiopoietin signaling.\n",
    "A total of 29 enriched pathways were identified.\n",
    "Disease Ontology:\n",
    "Target genes of candidate miRNAs were associated with diseases such as:\n",
    "Septic shock (most significant).\n",
    "Acute kidney injury.\n",
    "Rheumatoid arthritis.\n",
    "Precursor cell lymphoblastic leukemia.\n",
    "\n",
    "D. Protein-Protein Interaction Networks (PINs)\n",
    "\n",
    "PINs were constructed for each candidate miRNA to elucidate their regulatory functions.\n",
    "Example: miR-210 regulates proteins involved in immune responses (e.g., HMGB1, MAX, and TP53I11).\n",
    "\n",
    "E. Functional Analysis\n",
    "\n",
    "Gene Ontology (GO) Terms:Common GO terms for candidate miRNAs included:\n",
    "Regulation of apoptosis.\n",
    "Positive regulation of biosynthetic processes.\n",
    "Regulation of transcription.\n",
    "\n",
    "Apoptosis and Biosynthetic Processes:Two key biological processes in sepsis progression:\n",
    "Dysregulated apoptosis contributes to immune system paralysis.\n",
    "Altered biosynthesis reflects metabolic shifts during sepsis.\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.16"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
